Revenue declines at medical devices company

Tissue Regenix Group Regenerative medical devices company, Tissue Regenix has revealed a challenging first half, with revenues falling 6% to $13.8m on the back of regulatory, reimbursement, and production issues.

BioRinse® sales slipped 7% to $9.8m as delays in obtaining regulatory approvals impacted the onboarding of new customers Meanwhile, dCELL® revenue decreased 4% year-on-year to $4.0m, although it rose 16% compared with the second half of 2024. Adjuste... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...